We are live on ! Find out more
HELX icon

Franklin Genomic Advancements ETF
HELX

7 hedge funds and large institutions have $3.79M invested in Franklin Genomic Advancements ETF in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

999% more capital inflows, than outflows

Capital inflows: $1.66M | Capital outflows: $151K

6.68% more ownership

Funds ownership: 7.93% → 14.61% (+6.7%)

0% more funds holding

Funds holding: 7 → 7 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.33M
2
LPL Financial
LPL Financial
California
+$302K
3
Osaic Holdings
Osaic Holdings
Arizona
+$27.9K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$131K
2
Harbour Investments
Harbour Investments
Wisconsin
-$13.7K
3
BFCFSI
BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC.
Iowa
-$3.47K
4
UBS Group
UBS Group
Switzerland
-$2.94K

HELX Hedge Fund Activity: Q2 2026 in Review

7 of the 8,374 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q2 2026, worth a combined $3.79M — up 123% from $1.7M a quarter earlier.

Fund positioning in HELX was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 3 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.33M. The largest seller was Citadel Advisors, cutting an estimated $131K.

  • 7 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $3.79M of Franklin Genomic Advancements ETF stock for Q2 2026, up 123% quarter-over-quarter.
  • 1 fund opened new Franklin Genomic Advancements ETF positions in Q2 2026 and 1 closed out, a net change of 0 holders.
  • The largest Franklin Genomic Advancements ETF buyer in Q2 2026 was Susquehanna International Group, an estimated $1.33M added.
  • The largest Franklin Genomic Advancements ETF seller in Q2 2026 was Citadel Advisors, an estimated $131K sold.

Based on aggregated 13F filings for Q2 2026.